Akari Therapeutics Shares Swing on Dual Patent Filings

Akari Therapeutics experienced significant price volatility following the company’s latest move to strengthen its intellectual property portfolio. The biopharmaceutical firm submitted two provisional patent applications for its PH1 compound, a development that has drawn mixed reactions from investors despite its potential to enhance the company’s competitive standing in cancer therapeutics.

Trading activity for Akari shares has been turbulent. After posting gains exceeding 9% over the previous week, the equity reversed course sharply on Friday. The stock declined by 8.82% to settle at $0.93, with intraday trading revealing price swings approaching 10%. This volatility comes amid generally positive news about the company’s intellectual property expansion.

Strategic Patent Expansion Details

Last Thursday, Akari filed two separate provisional applications with the... Read more...